EP Patent

EP3917502A1 — Methods of treating a patient having parkinson's disease

Assigned to Sumitomo Pharma America Inc · Expires 2021-12-08 · 4y expired

What this patent protects

Methods of treating a patient having Parkinson's disease, including treating "OFF" episodes and improving motor function, by administering apomorphine or a pharmaceutically acceptable salt thereof are disclosed herein. Supratherapeutic doses of apomorphine may be used. Ap…

USPTO Abstract

Methods of treating a patient having Parkinson's disease, including treating "OFF" episodes and improving motor function, by administering apomorphine or a pharmaceutically acceptable salt thereof are disclosed herein. Supratherapeutic doses of apomorphine may be used. Apomorphine therapy may be used in place of levodopa therapy, or apomorphine may be used to supplant or augment the first levodopa dose of the day. Apomorphine therapy may involve administration of two consecutive apomorphine doses at least 2 hours apart.

Drugs covered by this patent

Patent Metadata

Patent number
EP3917502A1
Jurisdiction
EP
Classification
Expires
2021-12-08
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma America Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.